Clinical Trials Browser

Phase 2 × Multi-centric Castleman's Disease × Sarcoma × Clear all

NCT05907759 2026-06-02

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

Phase 2 Recruiting

LymphoidSarcoma

Multi-centric Castleman's Disease, Lymphoma, Non-Hodgkin, Sarcoma, Kaposi, Lymphoma, Primary Effusion

NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

Phase 2 Completed

8 enrolled 18 charts

LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi